CONMED Quarterly Income Statement
NYSE: CNMDHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CONMED revenue and earnings
In the quarter ended Jun 30, 2026, CONMED generated $343.5 million in revenue, up 6.9% from the same quarter a year earlier. Net income was $23.1 million (+282.2% year over year), for a net margin of 6.7% versus a median of 4.5% in the prior 5 quarters. Gross margin was 57.5% (up from 55.3%) and operating margin 10.6%.
Diluted earnings per share came in at $0.77, up from $0.19.
Summary generated from market data by MetaCap's automated system. Methodology
CONMED income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 343.49M | 373.20M | 337.93M | 342.35M | 321.26M | 345.94M | 316.70M | 332.10M | 312.27M | 327.05M | 304.58M | 317.65M |
| Revenue growth (YoY) | +6.92% | +7.88% | +6.70% | +3.09% | +2.88% | +5.78% | +3.98% | +4.55% | +5.69% | +30.37% | +10.72% | +14.60% |
| Cost of Revenue | 146.03M | 154.91M | 171.81M | 154.03M | 143.50M | 147.60M | 137.71M | 148.37M | 140.31M | 144.87M | 136.52M | 146.96M |
| Gross Profit | 197.46M | 218.28M | 166.12M | 188.32M | 177.75M | 198.34M | 179.00M | 183.73M | 171.97M | 182.18M | 168.06M | 170.69M |
| Operating Expenses | 161.05M | 181.66M | 154.24M | 150.16M | 161.79M | 145.84M | 113.29M | 136.62M | 136.95M | 131.99M | 137.76M | 143.27M |
| Research & Development | 15.50M | 14.90M | 13.90M | 14.14M | 12.95M | 13.18M | 13.56M | 14.10M | 13.59M | 14.03M | 12.46M | 13.57M |
| Selling, General & Admin | 145.55M | 166.76M | 140.34M | 136.02M | 148.85M | 132.67M | 99.73M | 122.52M | 123.36M | 117.96M | 125.30M | 129.70M |
| Operating Income | 36.41M | 36.62M | 11.88M | 38.16M | 15.96M | 52.50M | 65.71M | 47.11M | 35.01M | 50.19M | 30.30M | 27.42M |
| Interest Expense | 7.88M | 7.37M | 7.61M | 7.82M | 8.29M | 8.86M | 9.25M | 9.59M | 9.59M | 9.50M | 10.02M | 10.00M |
| Other Income (Expense) | 2.83M | — | — | -418.00K | — | — | — | — | — | — | — | — |
| Pretax Income | 31.35M | 29.25M | 4.27M | 29.92M | 7.67M | 43.64M | 56.45M | 37.51M | 25.42M | 40.68M | 20.28M | 17.42M |
| Income Tax | 8.28M | 12.51M | 1.41M | 8.50M | 1.64M | 9.89M | 7.47M | 7.54M | 5.71M | 7.61M | 4.44M | 3.69M |
| Net Income | 23.07M | 16.74M | 2.86M | 21.42M | 6.04M | 33.76M | 48.98M | 29.98M | 19.71M | 33.07M | 15.84M | 13.73M |
| Net Income growth (YoY) | +282.22% | -50.41% | -94.16% | -28.54% | -69.37% | +2.07% | +209.30% | +118.29% | +983.51% | +24.40% | -65.68% | — |
| EPS (Basic) | 0.77 | 0.55 | 0.09 | 0.69 | 0.19 | 1.09 | 1.59 | 0.97 | 0.64 | 1.07 | 0.52 | 0.45 |
| EPS (Diluted) | 0.77 | 0.54 | 0.09 | 0.69 | 0.19 | 1.09 | 1.57 | 0.96 | 0.63 | 1.05 | 0.50 | 0.43 |
| Shares Outstanding (Basic) | 30.07M | — | 30.95M | 30.95M | 30.97M | — | 30.86M | 30.81M | 30.78M | — | 30.74M | 30.66M |
| Shares Outstanding (Diluted) | 30.12M | — | 31.05M | 31.05M | 31.15M | — | 31.11M | 31.11M | 31.27M | — | 31.69M | 31.80M |
| EBITDA | — | 40.69M | 16.25M | 42.63M | 20.19M | 56.70M | 69.90M | 51.27M | 39.06M | 54.24M | 34.23M | 31.58M |
| Gross Margin | 57.49% | 58.49% | 49.16% | 55.01% | 55.33% | 57.33% | 56.52% | 55.32% | 55.07% | 55.70% | 55.18% | 53.73% |
| Operating Margin | 10.60% | 9.81% | 3.52% | 11.15% | 4.97% | 15.18% | 20.75% | 14.18% | 11.21% | 15.35% | 9.95% | 8.63% |
| Net Margin | 6.72% | 4.49% | 85.00% | 6.26% | 1.88% | 9.76% | 15.47% | 9.03% | 6.31% | 10.11% | 5.20% | 4.32% |
This table shows 12 quarterly periods of CONMED's income statement, from Q2 2026 back to Q2 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CNMD's reporting calendar. What is a income statement?